Oragenics Advances Phase IIa Concussion Trial, Eyes CNS Device Licensing
Oragenics provided a shareholder update on its Phase IIa trial of ONP-002 for concussion in Australia, plans for U.S. regulatory meetings, and a letter of intent to license a complementary CNS medical device.
Oragenics Inc. (NYSE American: OGEN) provided a shareholder update on Wednesday, highlighting progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury (mTBI) in Australia. The company reported active patient enrollment and dosing across multiple sites, with preparations underway to advance U.S. regulatory efforts. Oragenics expects to request a Type C meeting with the FDA in the second quarter of 2026 and submit an Investigational New Drug (IND) application by year-end 2026.
The update also revealed that Oragenics has signed a letter of intent to pursue licensing of a complementary central nervous system (CNS)-related medical device, signaling a strategic expansion beyond its lead therapeutic candidate. The company reported a cash balance of $6.1 million as of March 31, 2026.
The progress of ONP-002 is significant because concussion and mTBI affect millions annually, with no FDA-approved treatments currently available. Oragenics' proprietary intranasal delivery technology aims to deliver therapeutics directly to the brain, potentially offering a first-in-class treatment for these conditions. The company's platform has broader implications for other neurological disorders, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
The planned U.S. regulatory pathway is a critical step toward bringing ONP-002 to market. The Type C meeting with the FDA will allow Oragenics to discuss the design of a Phase 2b trial, which would follow the current Phase IIa study in Australia. Successful completion of these trials could position ONP-002 as a novel therapeutic option in an area of high unmet medical need.
The potential licensing of a CNS medical device complements Oragenics' therapeutic focus and could provide a synergistic approach to neurological care. While details of the device were not disclosed, the move underscores the company's commitment to building a comprehensive CNS portfolio.
For more details on the shareholder update, visit the full press release here. Additional updates and information about Oragenics are available in the company's newsroom at https://ibn.fm/OGEN.
The company's cash position of $6.1 million provides runway to advance these initiatives, though additional financing may be required to fully execute its clinical and regulatory plans. Investors and stakeholders will be watching for further updates on the Phase IIa trial results and the outcome of the FDA meeting.